Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Resverlogix Corp RVXCF


Primary Symbol: T.RVX

Healthcare Biotechnology
Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the... see more

Recent & Breaking News (TSX:RVX)

Resverlogix to Present at the European Society of Cardiology's ESC Congress 2019

GlobeNewswire August 14, 2019

Zenith Epigenetics and China-Based Newsoara Biopharma Announce Licensing Agreement for ZEN-3694

GlobeNewswire August 6, 2019

Resverlogix Announces Loan Reduction and Extension

GlobeNewswire August 2, 2019

Resverlogix Announces Publication on Apabetalone in Clinical Epigenetics

GlobeNewswire July 15, 2019

Resverlogix's BETonMACE Phase 3 Epigenetics Trial Completes Final Safety Visits

GlobeNewswire July 8, 2019

Zenith Epigenetics Announces Dosing of First Patient in Triple Negative Breast Cancer Trial with Pfizer

GlobeNewswire June 27, 2019

Resverlogix Provides Update on BETonMACE Phase 3 Epigenetics Trial

GlobeNewswire June 12, 2019

Resverlogix Announces Participation at Leading, International Scientific Conferences

GlobeNewswire June 10, 2019

Resverlogix Announces Closing of $15 Million Offering

GlobeNewswire June 7, 2019

IIROC Trade Resumption - RVX

Canada NewsWire May 15, 2019

Resverlogix Announces Pricing of Unit Offering

GlobeNewswire May 15, 2019

IIROC Trading Halt - RVX

Canada NewsWire May 15, 2019

Resverlogix Announces Proposed Offering of Units

GlobeNewswire May 14, 2019

Resverlogix Announces Publication on Apabetalone in High-Impact American Journal of Respiratory and Critical Care Medicine (AJRCCM)

GlobeNewswire May 6, 2019

Resverlogix Announces 3-Month Loan Extension

GlobeNewswire May 2, 2019

Resverlogix' BETonMACE Phase 3 Trial Successfully Reaches its Targeted 250 MACE Events

Thomson Reuters ONE April 18, 2019

Resverlogix' BETonMACE Phase 3 Trial Successfully Reaches its Targeted 250 MACE Events

GlobeNewswire April 18, 2019

Resverlogix Cognition Substudy of the BETonMACE Phase 3 Cardiovascular Trial Presented at the International Conference on Alzheimer’s & Parkinson’s Diseases

GlobeNewswire April 1, 2019

Resverlogix Announces $15.1 Million of Private Placements

GlobeNewswire April 1, 2019

Resverlogix Announces Ninth Positive Data Safety Monitoring Board Recommendation for Phase 3 Study of Apabetalone

GlobeNewswire March 27, 2019